Consistent with previous results [15], CREBBP/EP300 HAT inhibition shows activity in a subset of triple negative breast cancer (TNBC) cell lines, but we also noticed potent growth inhibition in ER+ cell lines (panel A in S1 Fig). This evidence concerns the gene CREBBP and triple-negative breast carcinoma.